How is Cotempla XR-ODT different to other brands of methylphenidate?

Cotempla XR-ODT is the first once-daily, extended-release, orally disintegrating tablet (ODT) formulation of the stimulant methylphenidate.

This ODT formulation is designed to dissolve on the tongue without the need to swallow with water.

Cotempla XR-ODT (methylphenidate) was approved in June 2017 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. It is not approved for use in adults.

Cotempla XR-ODT tablets are administered once daily in the morning.

Cotempla XR-ODT contains methylphenidate which is a Schedule II Controlled Substance, which means it has a high potential for abuse and dependence.

• Cotempla XR-ODT must be stored in a safe place, preferably locked, to prevent misuse.
• Cotempla XR-ODT must not be given to anyone else. Selling or giving away Cotempla XR-ODT may harm others and is against the law.
• Any unused or expired Cotempla XR-ODT should be disposed of through a medicine take-back program if available.

There are many brands of methylphenidate on the U.S market with multiple dosage forms, including:

• tablets (Ritalin)
• extended-release tablets (Concerta, Methylin ER, Relexxii)
• extended-release capsules (Adhansia XR, Aptensio XR, Jornay PM, Metadate CD, Ritalin LA)
• extended-release chewable tablets (Quillichew ER)
• extended-release orally disintegrating tablets (Cotempla XR-ODT)
• transdermal system (Daytrana)
• oral solution (Methylin)
• powder for extended-release oral suspension (Quillivant XR)

For more information, see What are the brands of methylphenidate?